NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…
Company Ended the Quarter With Cash of Approximately $527.0 MillionNEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:…
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold standard status as the premier…
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the…
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth…
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth…
PRESS RELEASE: REGULATED INFORMATION 4 February 2022, 07:00 CET Disclosure of a transparency notification Mechelen, Belgium, 4 February 2022 – Biocartis…
Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022Sub-analysis compared the immunogenicity of VLA15 in…